

# Tumor heterogeneity in the recurrence of epithelial ovarian cancer demonstrated by polycomb group proteins

Ting Gui<sup>1,\*</sup>  
Huimin Bai<sup>1,\*</sup>  
Jianfang Zeng<sup>1</sup>  
Zhaoji Zhong<sup>1</sup>  
Dongyan Cao<sup>1</sup>  
Quancai Cui<sup>2</sup>  
Jie Chen<sup>2</sup>  
Jiaxin Yang<sup>1</sup>  
Keng Shen<sup>1</sup>

<sup>1</sup>Department of Obstetrics and Gynecology, <sup>2</sup>Department of Pathology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, People's Republic of China

\*These authors contributed equally to this work

**Purpose:** To investigate tumor heterogeneity in the recurrence of epithelial ovarian cancer demonstrated by polycomb group (PcG) proteins.

**Methods:** Tissue microarrays containing matched primary and recurrent ovarian tumors from the same patients were constructed for detection of PcG protein expression. Survival analyses of clinicopathological parameters and expression of PcG proteins were performed on progression-free survival (PFS) and overall survival (OS) of patients. Genetic and epigenetic heterogeneity was explored in aspects of gene copy number and microRNA (miRNA) profiling.

**Results:** PcG proteins were heterogeneously expressed in primary versus recurrent tumors ( $P < 0.05$ ). In univariate survival analysis of the ovarian carcinoma cohorts, a significant association of intensive expression of BMI1 and EZH2 in first-onset lymph node metastases with shortened PFS was demonstrated ( $P = 0.010$ ,  $P = 0.019$ ); and a significant association of intensive expression of BMI1 and EZH2 in recurrent tumors with shortened OS was demonstrated ( $P = 0.042$ ,  $P = 0.047$ ). Importantly, BMI1 and EZH2 expression provided significant independent prognostic parameters in multivariate analyses ( $P < 0.05$ ). Gene amplification did not always coincide with PcG protein expression. Eight miRNAs were found to be downregulated in recurrent tumors, among which miR-298 might indirectly regulate the expression of EZH2 through transcription factor ILF3.

**Conclusion:** Tumor heterogeneity exists in the recurrence of epithelial ovarian cancer, manifested by PcG protein expression and underlying genetic and epigenetic alterations. Intensive expression of BMI1 and EZH2 are predictors of earlier relapse and shorter OS, independent of grade and chemotherapy sensitivity. EZH2 and miR-298 have great potential to be new targets for treatment of recurrent ovarian cancer.

**Keywords:** PcG protein, miRNA

## Introduction

Ovarian cancer is the leading cause of death due to gynecological malignancies all over the world. Serous ovarian cancer represents the most common histology and is responsible for the majority of advanced-stage cases.<sup>1</sup> Most women with advanced ovarian cancers recur and ultimately succumb to their diseases. Treatment failure has often been attributed to chemoresistance. However, emerging evidence indicates an important role of tumor heterogeneity.<sup>2</sup> Each case of tumor is thought to originate from a single progenitor cell.<sup>3</sup> As tumors develop, they undergo an evolutionary departure from a monoclonal state to a state consisting of multiple subclones.<sup>4</sup> Subpopulations of tumor cells present with significant discrepancies in morphology, protein expression, biological functions, and genetic characteristics. Cells that acquire advantageous

Correspondence: Jiaxin Yang; Keng Shen  
Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, People's Republic of China  
Tel/Fax +86 10 6521 2507  
Email yjx\_yangjiaxin@163.com; sk\_shenkeng@sina.com

mutations have stronger survival ability under selective pressure and become the origin of tumor relapse.

Polycomb group (PcG) proteins are key regulators of cell-fate decisions, essential for the normal development of organisms, by working as transcriptional repressors of several thousand genes controlling differentiation pathways during development.<sup>5</sup> A large number of clinical studies have also provided evidence that some PcG proteins are abnormally expressed in many cancers, and play a role in cancer invasion, metastasis, and progression, and thus can be viewed as molecular markers or prognostic indicators through silencing some tumor suppressor genes, correlating with noncoding RNA in oncogenesis, or regulating the stem cells.<sup>6</sup>

So far, investigations concerning tumor heterogeneity in the recurrence of ovarian cancer have been sparse. Our objectives in this study are therefore threefold: 1) to determine the expression pattern of PcG proteins in ovarian cancer recurrence, 2) to analyze the prognostic significance and clinical outcome of PcG proteins, and 3) to explore the underlying genetic and epigenetic alterations. Determining the molecular events that control this tumor trait might provide us potential targets for the treatment of ovarian cancer recurrence.

## Materials and methods

### Patient materials

Between January 2001 and December 2010, 100 patients with advanced ovarian serous cystadenocarcinoma (Fédération Internationale de Gynécologie et d'Obstétrique [FIGO] III–IV) were included in our study. Inclusive criteria were as follows: 1) patients underwent primary and secondary cytoreductive surgery at Peking Union Medical College Hospital (PUMCH), 2) patients did not receive neoadjuvant chemotherapy before surgery, and 3) patients received standard platinum/paclitaxel-based chemotherapy.

Matched formalin-fixed, paraffin-embedded (FFPE) tumor tissues from the same patients were collected from the Department of Pathology at PUMCH, including primary ovarian tumors at presentation (P), abdominal disseminated lesions at presentation (A), lymph nodes metastases at presentation (LN), and tumor lesions at relapse (R). Each sample was diagnosed by two independent pathologists.

Patient information, including age, FIGO stage, histological grade, ascites, CA125 level at presentation, CA125 level at relapse, and chemotherapy courses at complete remission, was collected from clinical database. Progression-free survival (PFS) was calculated from the date of cytoreductive

surgery to tumor recurrence. Overall survival (OS) was calculated from the date of diagnosis to patient death or the last follow-up. All investigations were performed in accordance with a protocol approved by the ethics committee at PUMCH.

### Tissue microarray construction

Tissue microarrays were constructed according to a method described previously.<sup>7</sup> Two tissue cores (diameter 1.0 mm, height 3–4 mm) taken from a donor block were placed in a recipient block using a tissue arraying instrument (MiniCore® Tissue Arrayer; Alphelys, Plaisir, France). Four tissue microarrays were constructed as research models for tumor heterogeneity. Up to December 2012, of the 100 patients included with advanced ovarian cancers, 76 patients had relapse diseases and 24 patients did not. Furthermore, of the 76 patients having relapse diseases, 50 patients had four matched samples (P + A + LN + R) reserved. For the other 26 patients having relapse diseases and the 24 patients having not, only paired primary ovarian tumor tissues and abdominal disseminated lesions at presentation were reserved.

### Immunohistochemistry (IHC)

Immunostaining was performed following a protocol described previously.<sup>8</sup> Primary and secondary antibodies are listed in Table S1. A negative control was obtained by normal non-immune IgG. Known immunostaining-positive slides were used as positive controls. Positive expression of PcG proteins was defined as presence of yellow-brown granules in nuclei. Staining results were evaluated by a semi-quantitative scoring criterion evaluating both the intensity and proportion of immunopositive cells.<sup>9</sup> A staining index was calculated by multiplying the staining intensity (negative =1, primrose yellow =2, yellowish brown =3, or dark brown =4) and the proportion of immunopositive cells ( $\leq 10\%$  =1, 10%–50% =2, 50%–75% =3,  $> 75\%$  =4). Points  $\leq 4$  were marked as (–), 4–8 as (+), 8–12 as (++), and 12–16 as (+++). For statistical analysis, (–) and (+) were counted as low expression, and (++) and (+++) as intensive expression. Results were assessed by two independent pathologists without knowing the sample information.

### Cell culture

Three epithelial ovarian cancer cell lines were investigated. Two cell lines, A2780 and SKOV3, were obtained from Cell Support Center, Institute of Basic Medical Science, Chinese Academy of Medical Sciences. The other one, OVCAR8, was kindly provided by the National Institute of Health,

USA. Cells were maintained in RPMI (Roswell Park Memorial Institute)-1640 with 10% fetal bovine serum (Gibco, Gaithersburg, MD, USA) in a humidified atmosphere with 5% CO<sub>2</sub> at 37°C.

## Fluorescence in situ hybridization (FISH)

The FISH reaction was performed as previously described.<sup>10</sup> Deparaffinized sections were treated with proteinase K (400 µg/mL) at 37°C for 30 minutes, denatured in 70% formamide, 2× standard saline citrate (SSC) at 75°C for 6 minutes. About 50 ng of FAM (carboxyfluorescein)-labeled (green) probe, mixed in a 20 µL hybridization mixture (containing 55% formamide, 2× SSC, and 2 µg human Cot-1 DNA<sup>®</sup>), was denatured at 75°C for 6 minutes and then hybridized to the denatured tissue microarray sections at 37°C for 24 hours. After washing, the slides were counterstained with 1 µg/mL DAPI (4',6-diamidino-2-phenylindole) in an antifade solution, and examined under a laser scanning confocal microscope (TCS SP5; Leica Microsystems, Wetzlar, Germany). FISH signals in over 300 cells in each specimen were counted. Gene amplification was defined as presence of six or more gene signals in tumor cells.<sup>11</sup> The probe sequence for gene *BM11* was 5'-ACG GTA GTA CCC GCT TTT AGG CAT ACA GAT TTA TGG TTG TGG CAT CAA TGA AGT ACC CTC CGG ACA TCA CAA ATA GGA CAA TAC TTG CTG G-3'. The probe sequence for gene *EZH2* was 5'-ATG TAC TCT GAT TTT ACA CGC TTC CGC CAA AGC ATT TGG TCC ATC TAT GTT GGG GGT ACA GTG ACT CTA AAC TCA TAC ACC TGT CTA CAT-3'.

## MicroRNA (miRNA) microarray expression profiling

Total RNA (≥100 ng) was labeled with miRNA Complete Labeling and Hyb Kit and hybridized on Human miRNA Microarray Kit (Agilent Technologies, Santa Clara, CA, USA), which contains 60,000 probes for 1,205 human miRNAs. Hybridization signals were detected by Microarray Scanner (Agilent Technologies), and the scanned images were analyzed with Feature Extraction (Agilent Technologies) software.

## RNA isolation and real-time polymerase chain reaction (PCR)

For FFPE tissues, total RNA including miRNA was collected using AllPrep DNA/RNA FFPE Kit (Qiagen, Valencia, CA, USA).<sup>12</sup> miRNA was reversed to cDNA using miRcute miRNA First-Strand cDNA Synthesis Kit (TIANGEN, Beijing, People's Republic of China). Primers for miR-298 were as follows: forward primer, 5'-ACA CTC AGC TGG

GAG CAG AAG CAG GGA G-3'; reverse primer, 5'-GGT GTC GTG GAG TCG-3'. Primers for miR-4261 were as follows: forward primer, 5'-ACA CTC AGC TGG GAG GAA ACA GGG ACC C-3'; reverse primer 5'-GGT GTC GTG GAG TCG-3'. Real-time PCR was performed on an Applied Biosystems 7500 Real-time PCR system (Applied Biosystems, Foster City, CA, USA) with SuperReal Premix Kit and miRcute miRNA qPCR Detection Kit (SYBRGreen) (TIANGEN). The results were analyzed using a comparative method of 2<sup>-ΔΔCT</sup>.<sup>13</sup> Each sample was tested in triplicate.

## Luciferase reporter assay

Luciferase reporter vectors were constructed by cloning miR-4261 and miR-298 into pcDNA6.2 vector (Invitrogen; Thermo Fisher Scientific, Waltham, MA, USA), 3'-untranslated region (UTR) of ZNF207 and 3'-UTR of ILF3 into pGL3 vector (Invitrogen), ZNF207 and ILF3 into pcDNA3.1 vector (Invitrogen), and promoter of EZH2 into pGL3 vector (Invitrogen). SKOV3 cells were cotransfected with pcDNA6.2 or pcDNA3.1 vector and pGL3 vector by Lipofectamine 2000. After 48 hours, luciferase assays were performed using the dual luciferase reporter assay system (Promega Corporation, Fitchburg, WI, USA). Firefly luciferase activity was normalized to Renilla luciferase activity for each sample. All assays were performed in triplicate.

## Statistical analyses

Statistical analyses were performed with SPSS 19.0 software. Student's *t*-test and Wilcoxon signed rank test were used to compare the differences between two independent samples and paired samples from the same patients. Kaplan–Meier analysis and Cox model were used to study the risk factors of PFS and OS. *P*<0.05 was considered significant statistically.

## Results

### Tumor heterogeneity demonstrated by PcG protein expression in the recurrence of ovarian cancer

#### PcG protein expression in different tumor tissues

PcG protein family mainly includes 12 members, EZH2, EED, SUZ12, BMI1, MEL18, RING1, RING2, CBX2, CBX4, PHF1, PHC1, and RYBP. IHC staining indicated that seven proteins (BMI1, EZH2, CBX2, CBX4, PHF1, RING1, and RING2) had significantly higher expression levels in recurrent tumors than primary ovarian tumors at presentation (*P*<0.05) (Table 1 and Figure 1). Furthermore, three proteins, BMI1, EZH2, and RING2, showed significantly elevated expression levels in lymph node metastases at pre-

**Table 1** Staining index for 12 PcG proteins in four groups of ovarian tumor tissues

PcG proteins (n=12)	Primary ovarian tumor tissues at presentation (n=100×2)	Abdominal disseminated lesions at presentation (n=100×2)	Lymph node metastatic lesions at presentation (n=50×2)	Recurrent tumor tissues at relapse (n=50×2)	Primary tumors tissues vs lymph node metastatic lesions P-value*	Primary tumor tissues vs recurrent tumor tissues P-value*
<b>BMI1</b>	7.68±3.48	7.92±3.33	8.07±3.10	9.96±3.33	0.03	<0.001
MEL18	7.50±2.53	7.16±2.50	7.05±2.14	7.95±2.76	\	\
<b>RING1</b>	5.07±1.83	5.33±2.47	5.38±1.58	6.98±3.31	\	<0.001
<b>RING2</b>	5.64±1.50	5.66±1.26	5.97±0.99	6.44±1.84	0.041	<0.001
<b>CBX2</b>	5.29±1.07	5.37±1.15	5.35±0.78	5.49±1.28	\	<0.001
<b>CBX4</b>	7.01±2.77	6.99±2.98	6.93±1.81	8.36±3.31	\	0.034
PHC1	6.70±3.09	6.44±3.27	6.57±1.87	6.72±2.90	\	\
<b>PHF1</b>	7.20±3.16	7.35±3.18	7.24±2.06	8.12±3.16	\	0.017
RYBP	6.22±2.48	6.10±2.75	6.29±2.36	6.43±2.40	\	\
<b>EZH2</b>	7.35±3.17	8.01±3.34	9.08±3.79	9.82±3.87	0.028	<0.001
EED	6.10±2.50	5.88±2.16	6.03±2.05	5.94±2.33	\	\
SUZ12	6.43±2.16	6.36±2.39	6.33±1.14	6.69±2.48	\	\

**Notes:** \*Wilcoxon signed rank test. A semi-quantitative scoring criterion is used, and a staining index (values 1 to 16), obtained as the intensity of positive staining (negative =1, weak =2, moderate =3, or strong =4 scores) and the proportion of immunopositive cells of interest ( $\leq 10\%$  =1,  $>10\%$  to  $\leq 50\%$  =2,  $>50\%$  to  $\leq 70\%$  =3,  $>75\%$  =4 scores), is calculated. Proteins that show significant expression differences between primary and recurrent tumor tissues are shown in bold.

**Abbreviation:** PcG, polycomb group.

sentation than in primary ovarian tumors ( $P<0.05$ ) (Table 1). However, no significant differences were observed in 12 PcG protein expression in primary ovarian tumor tissues versus abdominal disseminated lesions at presentation (Table 1).

### Relationship between clinicopathological variables, PcG protein expression, and recurrence and survival of ovarian cancer patients

In univariate survival analysis, to confirm the representativeness of the ovarian carcinomas in our study, we analyzed established prognostic predictors of patient prognosis. Kaplan–Meier analysis demonstrated a significant impact of FIGO stage and histological grade on PFS before recurrence ( $P=0.024$ ,  $P=0.010$ ), and FIGO stage, histological grade, and chemotherapy sensitivity on OS ( $P=0.016$ ,  $P=0.002$ ,  $P<0.001$ ) (Table S2). Patients with tumors having intensive expression of BMI1 and EZH2 in lymph node metastases at presentation had earlier relapse ( $P=0.01$ ,  $P=0.019$ ) (Table S3). Patients with tumors having intensive expression of BMI1, EZH2, and PHF1 in recurrent tumor tissues had shorter OS ( $P=0.042$ ,  $P=0.047$ , and  $P=0.010$ ) (Table S3).

The following multivariate analysis demonstrated that intensive expression of BMI1 and EZH2 in lymph node metastases were prognostic factors of early recurrence, independent of histological grade, and intensive expression of BMI1, EZH2, and PHF1 in recurrent lesions were

predictors of poor OS, independent of histological grade and chemotherapy sensitivity (Table 2).


### Tumor heterogeneity in genetic and epigenetic features associated with heterogeneous expression of PcG proteins

#### Amplification of PcG genes *BMI1* and *EZH2* in recurrent ovarian tumors

FISH was performed in tissue microarray sections containing 50 pairs of primary and recurrent ovarian tumor tissues to determine whether the upregulation of PcG protein expression was correlated with gene copy number increment. The results demonstrated that fluorescence signals were informative in 30 (30/50, 60%, BMI1) or 36 (36/50, 72%, EZH2) pairs of specimens, among which 21 (21/30, 70%, BMI1) and 27 (27/36, 75%, EZH2) recurrent tumor tissues had intensive protein expression. Only six (6/30, 20%, BMI1) and eight (8/36, 22%, EZH2) pairs of samples showed gene amplification and protein expression upregulation in recurrent lesions simultaneously (Figure 2). Amplification of BMI1 or EZH2 was not observed in the other 15 (15/30, 50%, BMI1) or 19 (19/36, 53%, EZH2) recurrent tumors.

#### miRNA microarray expression profiling in paired primary and recurrent ovarian tumor tissues

Since gene amplification could only explain the heterogeneous expression of PcG proteins in some cases of ovarian



**Figure 1** Immunohistochemical staining of seven polycomb group proteins in matched specimens from the same patients with ovarian serous cystadenocarcinoma. Increased staining could be observed in recurrent tumors.

**Note:** Bars represent 200  $\mu$ m.

**Abbreviations:** A, abdominal disseminated lesions at presentation; LN, lymph node metastases at presentation; P, primary ovarian tumor tissues at presentation; R, recurrent lesions.

cancer recurrence, we then performed miRNA microarray expression profiling in six pairs of primary and recurrent ovarian cancer tissues. Eight miRNAs were identified down-regulated in recurrent lesions compared with primary tumors (more than a twofold change,  $P < 0.05$ ) (Figure 3A).

Through Target Scan Software and Transfect Database, we found two transcription factors for the PcG core gene *EZH2*; *ZNF207* and *ILF3* were also the targets of miR-4261 and miR-298, respectively. To further confirm the reliability of miRNA microarray, we performed real-time PCR in 36 pairs of primary and recurrent ovarian tumors,

results indicating that miR-4261 and miR-298 indeed were downregulated in the recurrent lesions ( $P = 0.024$ ,  $P = 0.03$ ) (Table S4).

Luciferase reporter assays were then performed, and the results showed that miR-4261 and miR-298 significantly suppressed the luciferase activity of *ZNF207* and *ILF3* ( $P = 0.001$ ,  $P = 0.008$ ), and in turn, *ZNF207* and *ILF3* significantly promoted the luciferase activity of *EZH2*-promoter reporter plasmid ( $P = 0.000$ ,  $P = 0.000$ ) (Figure 3B). Nevertheless, the luciferase activity of *ZNF207* and *ILF3* was not affected by miRNA negative control, and the empty-pGL3-*EZH2*

**Table 2** Multivariate analysis of clinicopathological parameters and PcG proteins expression on patients with ovarian serous cystadenocarcinoma

PcG proteins expression and clinicopathological parameters	Relative risk	95% confidence interval	P-value
<b>BMII-LN<sup>Re</sup></b>			
FIGO stage	3.652	0.790–16.886	0.097
Histological grade	4.743	1.987–11.320	0.002
BMII-LN	3.679	1.421–9.522	0.007
<b>EZH2-LN<sup>Re</sup></b>			
FIGO stage	3.675	0.792–17.056	0.096
Histological grade	5.657	1.664–19.230	0.006
EZH2-LN	2.872	1.235–6.681	0.014
<b>BMII-R<sup>OS</sup></b>			
FIGO stage	4.489	0.769–26.211	0.095
Histological grade	3.271	1.277–8.382	0.014
Chemotherapy course at remission	7.127	1.841–27.594	0.004
BMII-R	1.363	1.146–1.904	0.030
<b>EZH2-R<sup>OS</sup></b>			
FIGO stage	0.827	0.054–12.694	0.891
Histological grade	2.604	1.026–6.613	0.044
Chemotherapy course at remission	3.190	1.825–12.336	0.007
EZH2-LN	2.757	0.534–14.228	0.043
<b>PHF1-R<sup>OS</sup></b>			
FIGO stage	3.249	0.529–19.976	0.203
Histological grade	4.900	1.505–15.949	0.008
Chemotherapy course at remission	5.631	1.474–21.506	0.011
PHF1-R	1.385	1.144–2.030	0.047


**Abbreviations:** Re, multivariate analysis on relapse of patients; OS, multivariate analysis on overall survival of patients; LN, lymph node metastases at presentation; R, tumor tissues at relapse; PcG, polycomb group.

reporter plasmid was also unaffected by transfection with ILF3/ZNF207.

To further validate whether EZH2 is negatively regulated by miR-4261 and miR-298, we transfected miR-4261 and miR-298 mimics into A2780 and OVCAR8 ovarian cancer cells and examined ZNF207, ILF3, and EZH2 mRNA and protein levels. The transfection efficiency was confirmed by real-time PCR and fluorescence (Figure 3C). miR-4261 and miR-298 upregulation led to a significant reduction of ZNF207 and ILF3, respectively, at mRNA and protein levels in A2780 and OVCAR8 cells (Figure 3D) (for ZNF207,  $P=0.001$  both; for ILF3,  $P=0.000$ ,  $P=0.001$ ). However, EZH2 expression was only concomitantly reduced significantly by miR-298 overexpression (Figure 3D) ( $P=0.001$  both).

## Discussion

Although accumulating evidence demonstrates tumor heterogeneity in ovarian cancer,<sup>14–17</sup> little attention has been




**Figure 2** Genetic heterogeneity underlying the heterogeneous expression of polycomb group proteins. Amplification of BMII and EZH2 was observed by fluorescence in situ hybridization in recurrent tumor tissues, with intensive expression of proteins detected by immunohistochemistry simultaneously. (A) BMII signals in primary tumors. (B) BMII signals in recurrent tumors. (C) EZH2 signals in primary tumors. (D) EZH2 signals in recurrent tumors.

**Note:** Bars represent 25  $\mu$ m.

focused on the recurrent diseases and the incorporation of tumor heterogeneity into clinical applications, such as prediction of patient prognosis and exploration of potential therapeutic targets.

PcG proteins were originally identified in *Drosophila* as regulators of *HOX* (homeotic box) gene during development that antagonizes gene activation by the TrxG (Trithorax group) proteins.<sup>18</sup> In mammals, PcG proteins are also implicated in *HOX* gene suppression, which may contribute to aberrant cellular proliferation and carcinogenesis.<sup>19</sup> Studies have shown that abnormal expression of PcG proteins is favorably associated with poor clinical outcome in diverse human cancers. However, to our best knowledge, there is little information about prognostic status of PcG proteins in ovarian cancer recurrence. In our study, seven members of the PcG protein family were upregulated in recurrent lesions, confirming that tumor heterogeneity existed in primary versus recurrent tumors at protein expression level. Through survival analyses, we found that intensive expression of BMII and EZH2 were predictors of earlier recurrence and shorter OS, independent of clinical parameters, such as histological grade and chemotherapy sensitivity.

These findings raise an important question of what mechanisms might be involved in the heterogeneous expression of PcG proteins in the recurrent lesions. Genetic/epigenetic



**Figure 3** Epigenetic heterogeneity underlying the heterogeneous expression of polycomb group proteins.

**Notes:** (A) miRNA microarray expression profiling of six pairs of primary and recurrent ovarian tumor tissues: heat map shows eight downregulated (fold change  $>2$ ) miRNAs in recurrent tumors. (B) Luciferase reporter assay: (B1) miR-4261 and miR-298 significantly suppressed the luciferase activity of ZNF207 and ILF3 ( $P=0.001$ ,  $P=0.008$ ); (B2) ZNF207 and ILF3 significantly promoted the luciferase activity of EZH2-promoter reporter plasmid ( $P=0.000$ ,  $P=0.000$ ). (C) Transfection of miR-4261 (C1 and C3) and miR-298 (C2 and C4) mimics into ovarian cancer cells, A2780 and OVCAR8, confirmed by real-time polymerase chain reaction and fluorescence. (D) Expression of ZNF207, ILF3, and EZH2 in ovarian cancer cells after miR-4261 and miR-298 upregulation: (D1, D2, and D4) a significant reduction of ZNF207 and ILF3 at mRNA and protein levels was observed (for ZNF207,  $P=0.001$  both; for ILF3,  $P=0.000$ ,  $P=0.001$ ); (D3 and D4) EZH2 expression was only concomitantly reduced significantly by miR-298 overexpression ( $P=0.001$  both).

**Abbreviation:** miRNA, microRNA.

heterogeneity is a ubiquitous characteristic of neoplasms, and is fundamental to the process of neoplastic progression.<sup>20,21</sup> Gene amplification is a common pathological mechanism of gene overexpression in human cancers. To determine whether the upregulation of BMI1 and EZH2 expression was caused by gene amplification, the status of gene copy number was examined by FISH. In our 30/36 pairs of informative cases by both IHC and FISH simultaneously, intensive expression of BMI1 and EZH2 were detected in about 20% of ovarian cancers that had gene amplification. Our results indicated that genetic heterogeneity indeed existed in primary versus recurrent lesions, but the expression level of PcG proteins did not always coincide with gene amplification, and other mechanisms should be involved in the regulation, as epigenetic alterations.

Therefore, we next performed miRNA microarray expression profiling in six pairs of primary and recurrent ovarian

cancer tissues, and found eight miRNAs downregulated in recurrent lesions. Through Target Scan Software and Transfect Database, we found that miR-4261 and miR-298 had seed match with ZNF207 3'-UTR and ILF3 3'-UTR, and in turn, ZNF207 and ILF3 are transcription factors of EZH2 promoter, suggesting that miR-4261 and miR-298 might indirectly regulate the expression of EZH2 through intermediate factors.

This postulation was then confirmed by subsequent luciferase reporter assay. Our results demonstrated that the activities of luciferase reporters with ZNF207 and ILF3 were significantly inhibited by miR-4261 and miR-298, and in turn, the luciferase activity of EZH2-promoter reporter plasmid was significantly promoted by ZNF207 and ILF3. In addition, transfection of ovarian cancer cells with miR-4261 and miR-298 mimics caused a dramatic decrease in ZNF207 and ILF3 mRNA and protein levels. However,

EZH2 expression was only concomitantly reduced significantly by miR-298 overexpression. These findings provide evidence that miR-298 may repress EZH2 expression through intermediate transcription factor ILF3. Our results indicated that epigenetic heterogeneity also played an important role in ovarian cancer recurrence.

Overall, our study has investigated the role of tumor heterogeneity in ovarian cancer recurrence at two levels, expression of PcG proteins, and underlying genetic/epigenetic alterations. One problem posed by tumor heterogeneity is that the initial biopsy and testing results might not be representative for the residual tumor cells after first treatment, and accordingly not suitable as basis for the choice of subsequent treatment. As a result, tumor heterogeneity makes personalized medicine necessary, and identification of relapse-specific lesions may provide potential targets for the treatment.

## Conclusion

Tumor heterogeneity exists in the recurrence of ovarian cancer, manifested by PcG protein expression and underlying genetic and epigenetic alterations. Intensive expression of BMI1 and EZH2 are predictors of earlier relapse and shorter OS, independent of histological grade and chemotherapy sensitivity. Genes *EZH2* and *miR-298* have great potential to be new targets for treatment of recurrent ovarian cancer.

## Acknowledgments

This work is supported by National Natural Science Foundation of China (No 81172482) and National High Technology Research and Development Program of China (No 2012AA02A507).

## Author contributions

All authors contributed toward data analysis, drafting and revising the paper and agree to be accountable for all aspects of the work.

## Disclosure

The authors declare that no conflicts of interest exist.

## References

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. *CA Cancer J Clin*. 2014;64(1):9–29.
2. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. *N Engl J Med*. 2012;366(10):883–892.
3. Nowell PC. The clonal evolution of tumor cell populations. *Science*. 1976;194(4260):23–28.
4. Durrett R, Foo J, Leder K, Mayberry J, Michor F. Intra-tumor heterogeneity in evolutionary models of tumor progression. *Genetics*. 2011;188(2):461–477.
5. Morey L, Helin K. Polycomb group protein-mediated repression of transcription. *Trends Biochem Sci*. 2010;35(6):323–332.
6. Lin YW, Chen HM, Fang JY. Gene silencing by the polycomb group proteins and associated with cancer. *Cancer Invest*. 2011;29(3):187–195.
7. Xie D, Sham JS, Zeng WF, et al. Heterogeneous expression and association of  $\beta$ -catenin, p16 and c-myc in multistage colorectal tumorigenesis and progression detected by tissue microarray. *Int J Cancer*. 2003;107(6):896–902.
8. Xie D, Zeng YX, Wang HJ, et al. Expression of cytoplasmic and nuclear Survivin in primary and secondary human glioblastoma. *Br J Cancer*. 2006;94(1):108–114.
9. Zhang F, Sui L, Xin T. Correlation of Bmi-1 expression and telomerase activity in ovarian cancer tissues. *Exp Oncol*. 2008;30(1):70–74.
10. Tang TC, Sham JS, Xie D, et al. Identification of a candidate oncogene SEI-1 within a minimal amplified region at 19q13.1 in ovarian cancer cell lines. *Cancer Res*. 2002;62(24):7157–7161.
11. Yang GF, He WP, Cai MY, et al. Intensive expression of Bmi-1 is a new independent predictor of poor outcome in patients with ovarian carcinoma. *BMC Cancer*. 2010;10:133.
12. Kotorashvili A, Ramnauth A, Liu C, et al. Effective DNA/RNA co-extraction for analysis of microRNAs, mRNAs, and genomic DNA from formalin-fixed paraffin-embedded specimens. *PLoS One*. 2012;7(4):e34683.
13. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the  $2^{-\Delta\Delta CT}$  method. *Methods*. 2001;25(4):402–408.
14. Bashashati A, Ha G, Tone A, et al. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. *J Pathol*. 2013;231(1):21–34.
15. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. *Nature*. 2011;474(7353):609–615.
16. Cooke SL, Ng CK, Melnyk N, et al. Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. *Oncogene*. 2010;29(35):4905–4913.
17. Khalique L, Ayhan A, Weale ME, Jacobs IJ, Ramus SJ, Gayther SA. Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours. *J Pathol*. 2007;211(3):286–295.
18. Schuettengruber B, Chourrout D, Vervoort M, Leblanc B, Cavalli G. Genome regulation by polycomb and trithorax proteins. *Cell*. 2007;128(4):735–745.
19. Hodgson JW, Brock HW. Are polycomb group bodies gene silencing factories? *Cell*. 2011;144(2):170–171.
20. Merlo LM, Pepper JW, Reid BJ, Maley CC. Cancer as an evolutionary and ecological process. *Nat Rev Cancer*. 2006;6(12):924–935.
21. Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell*. 2000;100(1):57–70.

## Supplementary materials

**Table S1** Details of primary and secondary antibodies used for immunohistochemical staining

Antibodies	Dilution	Supplier
Mouse anti-human BMI1	1:200	Abcam, Cambridge, UK
Rabbit anti-human RING1	1:250	Abcam, Cambridge, UK
Goat anti-human RING2	1:100	Abcam, Cambridge, UK
Rabbit anti-human PHF1	1:50	Abcam, Cambridge, UK
Goat anti-human MEL18	1:500	Santa Cruz Biotechnology, CA, USA
Goat anti-human PHC1	1:200	Santa Cruz Biotechnology, CA, USA
Goat anti-human CBX2	1:200	Santa Cruz Biotechnology, CA, USA
Rabbit anti-human CBX4	1:200	Abcam, Cambridge, UK
Mouse anti-human RYBP	1:600	Abcam, Cambridge, UK
Rabbit anti-human EZH2	1:200	Cell Signaling, Danvers, MA, USA
Rabbit anti-human EED	1:200	Abcam, Cambridge, UK
Mouse anti-human SUZ12	1:500	Abcam, Cambridge, UK
MaxVision™ HRP-Polymer	\	Maixin Biological Technology Development
goat anti-mouse/rabbit IHC Kit		Company, Fuzhou, People's Republic of China
MaxVision™ HRP-Polymer	\	Maixin Biological Technology Development
rabbit anti-goat IHC Kit		Company, Fuzhou, People's Republic of China

**Abbreviations:** HRP, horseradish peroxidase; IHC, immunohistochemistry.

**Table S2** Univariate analysis of clinicopathological parameters on prognosis of patients with ovarian serous cystadenocarcinoma (log-rank test)

Clinicopathological parameters	Number of cases	Tumor-free survival before relapse, months	P-value	Overall survival, months	P-value
Age, years			<b>0.257</b>		<b>0.432</b>
≤54	56	31.9		85.7	
>54	44	40		96.2	
FIGO stage			<b>0.024</b>		<b>0.016</b>
III	95	35.8		92.4	
IV	5	18.9		42.2	
Histological grade			<b>0.010</b>		<b>0.002</b>
G1	26	36.3		96.8	
G2 and G3	74	14.3		47.7	
Ascites			0.733		0.181
No	28	36.1		102.6	
Yes	72	34.2		84.4	
≤4	76	35		102.4	
>4	24	24		45.8	
CA125 level at presentation, U/mL			0.512		0.176
≤2,174	73	33.1		93.9	
>2,174	27	37.5		79.2	
CA125 level at relapse, U/mL			0.147		0.063
≤133	49	28.7		99.8	
>133	25	21.8		75.8	
Chemotherapy course at complete remission			0.468		≤0.001

**Abbreviation:** FIGO, Fédération Internationale de Gynécologie et d'Obstétrique.

**Table S3** Univariate analysis of PcG protein expression on prognosis of patients with ovarian serous cystadenocarcinoma (log-rank test)

PcG protein expression levels in different tumor samples	Number of cases	Progression-free survival, months	P-value	Overall survival, months	P-value
<b>BMII</b>					
Primary					
Low	63	34.4	0.529	89.6	0.668
Intensive	37	33.2		88.6	
Abdominal					
Low	60	33.6	0.998	101.1	0.154
Intensive	40	33.9		82.7	
Lymph node					
Low	19	37.2	<b>0.010</b>	99.8	0.330
Intensive	20	20.7		83.1	
Recurrent					
Low	19	25	0.707	101.6	<b>0.042</b>
Intensive	32	27.8		65.7	
<b>EZH2</b>					
Primary					
Low	70	34.3	0.899	89.5	0.206
Intensive	30	31.3		86.7	
Abdominal					
Low	63	36.9	0.282	90.5	0.763
Intensive	37	27.5		88.9	
Lymph node					
Low	18	36.5	<b>0.019</b>	89.4	0.350
Intensive	21	23		88.2	
Recurrent					
Low	21	31.2	0.195	93.2	<b>0.047</b>
Intensive	30	25.6		68.9	
<b>RING1</b>					
Primary					
Low	85	35.2	0.369	91.7	0.452
Intensive	15	26.5		88.5	
Abdominal					
Low	86	36.2	0.057	89.1	0.418
Intensive	14	27.6		86.1	
Lymph node					
Low	33	30.6	0.465	93.3	0.447
Intensive	6	22.7		87.2	
Recurrent					
Low	30	32.5	0.154	99.3	0.205
Intensive	21	26.8		81.6	
<b>RING2</b>					
Primary					
Low	83	34.8	0.673	92.9	0.186
Intensive	17	23.8		74.1	
Abdominal					
Low	84	33.9	0.798	94.6	0.330
Intensive	16	32.1		85.4	
Lymph node					
Low	35	28.3	0.760	118.6	0.426
Intensive	4	32		98.2	
Recurrent					
Low	34	27.2	0.706	90.5	0.546
Intensive	17	25.9		88.9	
<b>CBX2</b>					
Primary					
Low	83	35.5	0.272	92.8	0.186
Intensive	17	28.8		73.5	

(Continued)

**Table S3** (Continued)

PcG protein expression levels in different tumor samples	Number of cases	Progression-free survival, months	P-value	Overall survival, months	P-value
Abdominal					
Low	82	36.2	0.053	83.7	0.055
Intensive	18	25.7		68.4	
Lymph node					
Low	34	30.9	0.066	100.8	0.280
Intensive	5	21.8		84.1	
Recurrent					
Low	42	26.4	0.987	91.2	0.695
Intensive	9	28.4		81.9	
<b>CBX4</b>					
Primary					
Low	75	34.2	0.839	108.5	0.099
Intensive	25	33.5		82.6	
Abdominal					
Low	75	36.5	0.252	96.9	0.386
Intensive	25	28.1		86.6	
Lymph node					
Low	31	29.7	0.539	101.8	0.611
Intensive	8	25.6		90.4	
Recurrent					
Low	31	29.2	0.629	97.7	0.285
Intensive	20	25.2		83.8	
<b>PHFI</b>					
Primary					
Low	70	34	0.954	104.4	0.113
Intensive	30	34.9		83.1	
Abdominal					
Low	70	35.6	0.421	91.4	0.314
Intensive	30	32.4		86.1	
Lymph node					
Low	34	30	0.754	60.8	0.429
Intensive	5	21		28.6	
Recurrent					
Low	30	29.4	0.544	114.7	<b>0.010</b>
Intensive	21	24.9		73.8	

**Abbreviation:** PcG, polycomb group.

**Table S4** Validation of miR-298 and miR-4261 downregulation in 36 pairs of primary and recurrent ovarian cancer tissues

No	has-miR-298 2 <sup>-ΔΔCT</sup>		has-miR-4261 2 <sup>-ΔΔCT</sup>	
	Primary tumors	Recurrent tumors	Primary tumors	Recurrent tumors
1	16.86±3.29	0.23±0.08	10.47±0.78	0.11±0.01
2	0.37±0.06	1.91±0.79	0.30±0.06	2.06±0.27
3	0.59±0.03	0.83±0.07	1.98±0.11	0.24±0.02
4	1.26±0.30	0.18±0.02	0.58±0.07	0.01±0.001
5	1.85±0.20	0.17±0.08	2.29±0.18	0.44±0.001
6	0.35±0.13	1.09±0.18	0.26±0.03	0.94±0.07
7	1.01±0.53	1.63±0.31	0.47±0.06	4.10±0.24
8	0.36±0.04	0.66±0.04	1.66±0.24	5.25±0.27
9	1.87±0.33	0.80±0.10	1.97±0.06	0.72±0.05
10	0.03±0.01	0.15±0.04	0.59±0.02	0.10±0.001
11	5.23±1.58	4.23±0.80	0.01±0.001	0.01±0.001
12	0.12±0.03	1.01±0.07	15.92±1.81	5.66±0.46
13	1.08±0.07	3.52±0.16	3.46±0.27	0.72±0.05
14	2.41±0.11	1.61±0.30	6.50±0.55	10.97±1.36
15	1.19±0.40	3.21±0.18	1.14±0.03	3.05±0.33
16	9.11±1.02	0.49±0.07	17.21±0.39	0.06±0.01
17	1.85±0.27	3.45±0.65	1.69±0.08	3.25±0.43
18	1.52±0.03	0.53±0.14	4.47±0.08	0.28±0.02
19	0.94±0.49	0.71±0.13	5.93±0.66	0.14±0.01
20	2.44±0.40	0.10±0.01	5.57±0.49	0.23±0.01
21	1.26±0.12	0.07±0.01	0.18±0.01	0.35±0.02
22	4.58±0.45	0.30±0.08	4.26±1.02	0.33±0.05
23	0.17±0.05	1.22±0.24	1.86±0.38	0.46±0.03
24	0.99±0.06	1.85±0.37	0.02±0.001	3.03±0.19
25	0.045±0.007	2.14±0.32	13.97±1.26	1.05±0.13
26	16.50±1.40	1.27±0.29	21.69±2.01	0.08±0.01
27	15.03±1.60	0.45±0.07	8.88±0.30	0.08±0.01
28	3.46±0.66	0.92±0.16	8.47±0.16	0.93±0.04
29	4.83±1.54	0.52±0.05	5.10±0.16	7.96±0.98
30	2.34±0.70	2.62±0.52	4.68±0.16	6.96±0.90
31	0.60±0.12	0.85±0.13	0.46±0.04	0.05±0.01
32	12.89±1.25	0.94±0.18	5.23±0.68	0.61±0.07
33	31.46±6.93	9.18±0.54	7.47±0.43	1.91±0.14
34	3.81±1.00	1.91±0.46	15.17±0.51	15.59±2.46
35	0.08±0.03	0.03±0.01	0.11±0.02	0.01±0.001
36	2.08±0.14	0.53±0.04	0.32±0.04	0.59±0.01
P-value	0.03		0.024	

### OncoTargets and Therapy

### Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on

Submit your manuscript here: <http://www.dovepress.com/oncotargets-and-therapy-journal>

patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Dovepress